The Wegovy NAION lawsuits claim semaglutide drugs Wegovy and Ozempic can trigger sudden permanent vision loss. NAION means nonarteritic anterior ischemic optic neuropathy, a cutoff of blood flow to the front of the optic nerve often called an eye stroke.
Federal lawsuits focus on whether the maker gave a timely warning about that eye risk. The federal vision-loss cases now move together in one court. This article explains the injury, the claims, the evidence, and practical next steps.
Official resources:
- Read the official guidance from NIH — Use this primary source to verify the official guidance.
- Read the official guidance from FDA — Use this primary source to verify the official guidance.
Table of Contents
- What does NAION do to vision?
- What do the blindness lawsuits allege?
- What does the medical evidence show so far?
- What should patients and families do next?
What does NAION do to vision?
The National Eye Institute describes NAION as sudden damage from reduced blood flow to the front of the optic nerve. Patients often lose vision painlessly in one eye. The loss is usually permanent.
Sudden dimming, a dark shadow, or blurred central sight needs same-day eye care. Do not wait to see whether sight returns. An eye doctor must separate NAION from other causes of sudden loss.
What do the blindness lawsuits allege?
Plaintiffs allege Novo Nordisk failed to warn that Wegovy and Ozempic can cause NAION, according to ConsumerAffairs reporting in its ConsumerAffairs report on GLP-1 vision-loss suits. The core claim is failure to warn, not a challenge to weight or diabetes treatment itself. Federal cases were centralized as MDL No.
3163 in December 2025 in Pennsylvania federal court before Judge Karen S. Marston, as reported in a Levin Papantonio press announcement on the new GLP-1 MDL. ConsumerAffairs reports the vision-loss docket covers Ozempic, Wegovy, Rybelsus, Saxenda, Trulicity, Mounjaro and Zepbound. It is separate from the gastrointestinal-injury MDL.
What does the medical evidence show so far?
A July 2024 Mass Eye and Ear study in JAMA Ophthalmology found higher NAION incidence among semaglutide users. NPR, summarizing the study, reported about 4.3 times higher incidence in diabetes patients and 7.6 times higher in overweight or obesity patients. The study shows an association, not proof that the drug caused each case. European regulators treated the risk as real but rare. On June 6, 2025, Europe's PRAC concluded NAION is a very rare semaglutide side effect affecting up to 1 in 10,000 people, according to the European Medicines Agency in its EMA announcement on semaglutide and NAION.
The finding covered Ozempic, Rybelsus and Wegovy. The U.S. Food and Drug Administration listed NAION as a potential serious-risk signal for GLP-1 drugs in its October-December 2024 review and said it was assessing regulatory action. Novo Nordisk told NPR the injury cases lack merit. The company pointed to later research questioning causation and said randomized trials showed very few NAION cases. That clash over causation and warnings is now central to the litigation.
What should patients and families do next?
Europe's EMA directs patients who develop NAION while taking semaglutide to stop treatment. As of 2026, U.S.
labels still carried no NAION warning, according to the EMA meeting record, so the warning gap remains the dispute. Do not stop a prescribed drug without prompt medical advice. If sudden vision loss occurs during or after GLP-1 use, preserve facts early: Bring those records to prompt medical care first, then to an attorney for a case review.
- Write down each drug name, dose, pharmacy, start date, and stop date
- Record when vision changed, which eye changed, pain level, and prior eye disease
- Keep emergency, eye-doctor, imaging, prescription, and billing records together
- Ask the eye doctor to state the exact diagnosis in the chart